Abstract:

Objective To investigate the clinical significance of soluble erythropoietin receptor (sEPOR)in renal anemia(RA). Methods A total of 136 patients with RA and treated by erythropoietin(EPO)were enrolled. According to the degrees of anemia, they were classified into severe anemia group [hemoglobin(Hb)<60 g/L]and mild-to-moderate anemia group (Hb 60-120 g/L). A total of 100 healthy subjects undergoing a medical examination in Medical Center during the same period were enrolled as control group. The levels of sEPOR and the complexes of EPO/sEPOR were determined by enzyme-linked immunosorbent assay (ELISA). The level of parathyroid hormone (PTH) was determined by electrochemical immunoassay, the level of creatinine (Cr) was determined by picric acid method, and the results were analyzed statistically. Results Compared with the control group, the patients with severe and mild-to-moderate anemia had higher levels of sEPOR, the complexes of EPO/sEPOR, PTH and Cr (P<0.05).There was a good correlation of sEPOR and Hb in severe anemia group(r=-0.650,P<0.05), and there was no obvious correlation in mild-to-moderate anemia group(r=0.135,P<0.05). Conclusions The sEPOR level of patients with RA is higher that of control group. Peripheral blood sEPOR and EPO can be formed complexes. This study suggests that sEPOR is significant in the further research and clinical treatment of RA.

Key words: Soluble erythropoietin receptor, Erythropoietin, Renal anemia